Key result
Plasma ADMA levels increased significantly by 26.16% four months after coronary stenting in patients who developed in-stent restenosis, whereas TAFI levels showed no significant change.
Why the study?
Do plasma ADMA and TAFI levels predict in-stent restenosis following coronary stenting in patients with coronary artery disease?
Cohort (n=37)
No
Do plasma ADMA and TAFI levels predict in-stent restenosis following coronary stenting in patients with coronary artery disease?
p-value: p=0.0102
Elevated plasma ADMA levels, but not TAFI levels, are associated with a predisposition to in-stent restenosis following coronary stenting.
ADMA and TAFI may flag post-stent restenosis risk in CAD; hypothesis-generating and needs prospective validation.
The aim of this study was to examine the contribution of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS) and a novel marker of vascular endothelial dysfunction, and thrombin-activatable fibrinolysis inhibitor (TAFI), a risk factor for venous thrombosis, to the predisposition of coronary restenosis following stent implantation in coronary artery disease (CAD) patients. Thirty-seven patients with CAD were recruited from the Kobry El Obba Military Hospital, Cairo, Egypt. The patients were hospitalized for coronary angiography and coronary stenting (CS). Overnight fasting blood samples were collected from patients prior to CS and four months later for the determination of plasma ADMA and TAFI levels. The patients underwent follow-up coronary angiography to reveal in-stent restenosis. The results showed that plasma ADMA levels in CAD patients were significantly higher than those reported for healthy subjects. ADMA levels were significantly increased by 30% in CAD patients four months following CS. CAD patients who developed in-stent restenosis had a 35% increase in ADMA levels following CS. TAFI levels were not significantly changed after CS in CAD patients or in any of the subgroups. In conclusion, ADMA, but not TAFI, is linked to the predisposition of in-stent restenosis following CS.
No takes yet. Share an insight, caveat, or question.
KHALIFA et al. (2012) conducted a cohort in Coronary artery disease (n=37). Coronary stenting vs. Baseline (prior to stenting) and patients with patent stents was evaluated on Change in plasma ADMA levels 4 months after coronary stenting in patients who developed in-stent restenosis (p=0.0102). Plasma ADMA levels increased significantly by 26.16% four months after coronary stenting in patients who developed in-stent restenosis, whereas TAFI levels showed no significant change.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: